BrightSpring Health 株価情報 (NASDAQ: BTSG)

最新ニュース BrightSpring Health (NASDAQ:BTSG) 株価情報

BrightSpring Health

BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services and others. It generates the majority of its revenue from the Pharmacy Solutions segment.

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health Services Inc

BrightSpring Health Services, Inc. - Tangible Equity Unit

BTS GROUP HLDGS UNSP/ADR by BTS Group Holdings Public Company Ltd

BTS Group Holdings PLC

SentinelOne Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) reported fourth-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/03/b44288462/sentinelone-announces-fourth-quarter-and-fiscal-year-2025-financial-results">from the quarter</a>.
Q4 Earnings: SentinelOne reported fourth-quarter revenue of $225.5 million, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a> of $222.25 million, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The cybersecurity company reported fourth-quarter adjusted earnings of four cents per share, beating estimates of one cent per share.
Total revenue increased 29% year-over-year. Annualized recurring revenue (ARR)&nbsp;increased 27% year-over-year to $920.1 million as of Jan. 31. Customers with ARR of $100,000 or more grew 25% to 1,411 in the quarter. The company ended the period with $1.1 billion in cash, cash equivalents and investments.
&#8220;Our strong finish to the fiscal year reflects solid execution and the accelerating adoption of our platform solutions,&#8221; said Tomer Weingarten, CEO of SentinelOne.
&#8220;We&#8217;re on track to surpass&nbsp;$1 billion&nbsp;in ARR and revenue this year, a key milestone in our growth journey. For more than a decade, we&#8217;ve patented leading machine learning security models — now, we&#8217;re pioneering fully autonomous, agentic AI workflows.&#8221;
Outlook:&nbsp;SentinelOne expects first-quarter revenue of approximately $228 million versus estimates of $235.18 million. The company expects full-year 2026 revenue of $1.007 billion versus estimates of $1.012 billion.
Management is currently discussing the quarter on a conference call with investors and analysts that kicked off at 4:30 p.m. ET.
S Price Action: <a href="https://www.benzinga.com/quote/S" target="_blank" rel="noreferrer noopener">SentinelOne shares</a> were down 13.32% after-hours, trading at $16.73 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44290549/uipath-shares-plunge-after-q4-revenues-miss-weak-q1-guidance">UiPath Shares Plunge After Q4 Revenues Miss, Weak Q1 Guidance</a></li>
</ul>
Photo: Shutterstock.

Earnings

News

Guidance

After-Hours Center

Movers

Tech

SentinelOne Q4 Earnings: Revenue Beat, EPS Beat, Shares Sink On Soft Guidance

Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares moved higher on Wednesday as the software sector rebounded from weakness <a href="https://www.benzinga.com/news/earnings/25/03/44271317/dow-tumbles-over-1-as-trade-war-fears-grow-investor-sentiment-improves-slightly-but-fear-greed-index-remains-in-extreme-fear-zone">earlier this week</a>.
What To Know: On Monday, stocks across the software sector and broader market fell amid recession concerns due to uncertainty over tariffs and trade policy. Earlier this month, U.S. President Donald Trump implemented a 25% tariff on imports from Canada and Mexico, and raised tariffs on Chinese goods from 10% to 20%, according to <a href="https://abcnews.go.com/Business/timeline-trump-tariffs-canada-mexico-china/story?id=119506883">ABC</a>.
Trump later created an exception for USMCA-compliant goods, at least until April. The back-and-forth tariff news appears to have spooked investors about the future stability of pricing and supply chains. 
Trump also appeared to acknowledge the <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44222440/trump-says-economy-faces-period-of-transition-recession-ahead">possibility of a recession</a> in 2025 earlier this week, warning that there will be a "period of transition" as his administration makes significant changes.
The sector bounced back on Wednesday, potentially driven by reports that Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) <a href="https://www.benzinga.com/markets/equities/25/03/44271204/tsmc-proposes-joint-venture-with-nvidia-amd-and-broadcom-to-operate-intels-factories-report">proposed</a> a joint venture to Nvidia, AMD, Qualcomm and Broadcom, in which the venture would manage Intel&#8217;s factories.
According to the proposal, TSM would oversee Intel&#8217;s foundry division, which customizes chips for customers, but the company would not own more than a 50% stake in the venture. The Trump administration reportedly requested that TSM assist in strengthening Intel.
The news may be contributing to the rebound in stocks on Wednesday as investors may view the initiative as a way to enhance chip production efficiency and alleviate supply chain challenges. For software companies, such could improve the availability and performance of the hardware they rely on, benefiting companies like Palantir.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44284821/apple-stock-takes-a-bite-out-of-investors-as-siri-fumbles-ai-race">Apple Stock Takes A Bite Out Of Investors As Siri Fumbles AI Race</a>
PLTR Price Action: Palantir shares closed Wednesday up 7.17% at $83.65, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Shutterstock

PLTR

What's Going On With Palantir Stock Wednesday?

American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) released its fourth-quarter results after Wednesday's closing bell. Here's a look at the key figures from the quarter.  
The Details: American Eagle Outfitters reported quarterly GAAP earnings of 54 cents, in line with the analyst consensus estimate. Quarterly revenue of $1.6 billion was also in line with estimates.&nbsp;
Read More: <a href="https://www.benzinga.com/general/social-media/25/03/44286296/trump-media-technology-stock-drops-50-since-inauguration-day">Trump Media &amp; Technology Stock Drops 50% Since Inauguration Day</a>&nbsp;
For the fourth quarter, American Eagle reported: 
<ul>
<li>Total comparable sales increased by 3%, following the 8% reported comp growth last year.</li>
<li>Aerie comparable sales increased 6% on a 13% increase last year. American Eagle comparable sales grew 1% following 6% growth last year.</li>
<li>Gross margin of 37.3% reflected higher freight and product costs, offset by lower markdowns. BOW costs were roughly neutral.</li>
<li>Total ending inventory decreased 1% to $637 million. Inventory is healthy and well-positioned for the Spring season.</li>
</ul>
&#8220;2024 demonstrated significant progress on our Powering Profitable Growth Plan. The team delivered strong operating profit growth with positive momentum across our brands and channels as well as disciplined expense management and operating efficiencies,&#8221; commented Jay Schottenstein, AEO CEO.
Outlook:&nbsp;American Eagle sees a first-quarter revenue decline of mid-single digits and gross margin down year-over-year. The company sees a fiscal 2025 revenue decline in the low-single digits and gross margin down year-over-year. 
AEO Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, American Eagle Outfitters shares are down 5.24% after-hours at $11.45 on Wednesday.  
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Image: Shutterstock

American Eagle Outfitters Stock Slides After Q4 Report: Here's Why

Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) has outperformed the market over the past 20 years by 8.66% on an annualized basis producing an average annual return of 16.74%. Currently, Fiserv has a market capitalization of $118.62 billion. 
Buying $100 In FI: If an investor had bought $100 of FI stock 20 years ago, it would be worth $2,277.26 today based on a price of $211.33 for FI at the time of writing.
<h3>Fiserv's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741815073_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Fiserv Stock In The Last 20 Years

A Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Cybertruck had to be pulled out of Ventura Harbor in California, serving as a reminder that the electric vehicle is not a certified boat, despite past claims from CEO Elon Musk.
What Happened: A California Cybertruck owner may have learned the hard way that Musk's <a href="https://www.benzinga.com/news/22/10/29194879/cybertruck-doubling-up-as-a-boat-elon-musk-explains-the-mechanism-behind-it">past claims </a>about how waterproof the Cybertruck would be didn't end up materializing and the vehicle is not a boat.
While attempting to launch a jetski on Monday, the Cybertruck owner was unable to get the vehicle back out of the water, as reported by <a href="https://electrek.co/2025/03/11/tesla-cybertruck-sank-when-launching-a-jetski-after-musk-said-you-could-use-the-truck-as-a-boat/">Electrek </a>from a Safety for Citizens Facebook post.
The report said the Cybertruck fell into the harbor and the owner was able to get out of the vehicle before it sank and became completely submerged off the boat launch ramp. 
A Coast Guard diver attached cables and ropes to the vehicle while the Ventura City Fire Department, Vessel Assist, Tow Boat US and Harbor Patrol all assisted with the rescue effort.
Read Also: <a href="https://www.benzinga.com/news/23/12/36104426/elon-musk-wanted-to-make-a-vehicle-for-the-future-one-that-blade-runner-would-drive">Elon Musk Wanted To Make A Vehicle For The Future, One That Blade Runner Would Drive</a>
Why It's Important: Over the years and ahead of the first deliveries of the Cybertruck<a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/36032944/cybertruck-delivery-event-elon-musk-highlights-teslas-best-product-says-finally-the"> in November 2023</a>, Musk made numerous claims about the electric pickup truck that drew inspiration from James Bond films and "Blade Runner."
"Cybertruck will be waterproof enough to serve briefly as a boat, so it can cross rivers, lakes &amp; even seas that aren't too choppy," Musk <a href="https://x.com/elonmusk/status/1575508498430820352">tweeted </a>in September 2022.
Musk went on to say the goal of the Cybertruck was to be able to cross the water between SpaceX and South Padre Island, a distance of 1,100 feet.
The Cybertruck has a "wade mode" that makes navigating shallow water possible as it raises the ride height and "pressurizes the battery pack." The wade mode has to be activated with the vehicle's off-roading mode, which isn't covered by the warranty. It is unknown if wade mode was activated for this Cybertruck owner.
Musk said the Cybertruck was an impossible vehicle to be made, but worth it at the company's delivery launch.
"I think it's our best product," Musk said at the time.
Speaking of cars that can float and navigate water, did you know that Musk is the <a href="https://www.benzinga.com/general/entertainment/23/04/32100580/elon-musk-owns-an-iconic-1m-james-bond-movie-car-the-crazy-story-of-couple-who-bought-it-fo">owner of a car </a>from the James Bond movie "The Spy Who Loved Me."
Musk paid nearly $1 million for the vehicle in 2013. In the 1977 film, the sports car was able to transform into a submarine and fire missiles underwater. The car, one of eight used during the filming, is the only one that was used in the underwater scenes.
While the vehicle Musk bought doesn't actually transform into a submarine, it served partly as inspiration for the design of the Cybertruck and Musk's push to make the water have boat-like features.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/09/40736498/elon-musks-blade-runner-inspired-cybertruck-now-serves-pizza-on-the-side">Elon Musk&#8217;s &#8216;Blade Runner&#8217;-Inspired Cybertruck Now Serves Pizza On The Side</a></li>
</ul>
Photo: Shutterstock

TSLA

Musk Once Said 'Cybertruck Will Be Waterproof Enough To Serve Briefly As Boat': Owner Of Sunk EV Has Different Story To Tell

Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares are climbing in after-hours trading Wednesday after the company announced a new <a href="https://www.benzinga.com/pressreleases/25/03/b44288657/intel-appoints-lip-bu-tan-as-chief-executive-officer">chief executive officer. </a>
The Details: Intel said its board of directors has appointed Lip-Bu Tan, a former member of Intel&#8217;s board of directors, as chief executive officer, effective March 18. 
Tan will succeed Interim Co-CEOs David Zinsner and Michelle (MJ) Johnston Holthaus. Zinsner will remain executive vice president and chief financial officer, and Johnston Holthaus will remain CEO of Intel Products.
Read More: <a href="https://www.benzinga.com/general/social-media/25/03/44286296/trump-media-technology-stock-drops-50-since-inauguration-day">Trump Media &amp; Technology Stock Drops 50% Since Inauguration Day</a> 
Frank D. Yeary, who took on the role of interim executive chair of the board during the search for a new CEO, will revert to being the independent chair of the board upon Tan becoming CEO. Tan will also rejoin the Intel board of directors after stepping down from the board in August 2024.
&#8220;Lip-Bu is an exceptional leader whose technology industry expertise, deep relationships across the product and foundry ecosystems, and proven track record of creating shareholder value is exactly what Intel needs in its next CEO," Yeary said. 
"Throughout his long and distinguished career, he has earned a reputation as an innovator who puts customers at the heart of everything he does, delivers differentiated solutions to win in the market and builds high-performance cultures to achieve success,&#8221; Yeary added. 
The company had been searching for a new CEO since Dec. 1, 2024, when former CEO Pat Gelsinger stepped down after a challenging tenure at the company.
On his appointment, Tan said: "I am honored to join Intel as CEO. I have tremendous respect and admiration for this iconic company, and I see significant opportunities to remake our business in ways that serve our customers better and create value for our shareholders.&#8221; 
INTC Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Intel shares were up 11.41% at $23.04 at the time of publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44098232/markets-tank-after-trump-confirms-more-tariffs-heres-what-wall-street-is-saying">Markets Tank After Trump Confirms More Tariffs: Here&#8217;s What Wall Street Is Saying</a></li>
</ul>
Photo: Shutterstock

Management

INTC

Intel Stock Rallies After Company Names New CEO: What To Know

Offerings

AES Reports Pricing Of $800M Of Its 5.800% Senior Notes Due 2032

These updates will not impact IBM's Consolidated Financial Statements or its reportable segments.

IBM Says Making Changes To Its Reported Revenue Categories Within Its Software And Consulting Reportable Segments Beginning In Q1 Of 2025 - Filing

ViiV Healthcare announced Wednesday the latest findings from its <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">EMBRACE phase 2b study</a>.
The study found that N6LS (VH3810109 or VH109), given every four months in combination with monthly cabotegravir long-acting (CAB LA), kept viral levels suppressed in adults living with HIV who were already <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44280792/viiv-healthcares-investigational-broadly-neutralising-antibody-n6ls-successfully-maintains-viral-s" rel="noreferrer noopener">stable on treatment</a>.
These results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
Results from the EMBRACE study at the six-month primary endpoint showed:
<ul>
<li>96% of participants receiving VH109 60mg/kg intravenously (IV) and 88% receiving VH109 3000mg subcutaneously (SC) with rHuPH20 maintained HIV-1 RNA levels below 50 copies/mL, compared to 96% in the standard-of-care group.</li>
</ul>
<ul>
<li>Overall, 4% of the IV group and 6% of the SC group had HIV-1 RNA levels of 50 copies/mL or higher when measured at month six, compared to none in the standard-of-care group.</li>
</ul>
<ul>
<li>VH109 was generally well tolerated, though infusion site reactions were more frequent with SC administration, occurring in 14% compared to none with IV administration.</li>
</ul>
<ul>
<li>ViiV Healthcare will progress a six-month IV formulation of VH109 in combination with CAB LA for further evaluation in an EMBRACE part two trial.</li>
</ul>
The company also presented data from two phase 2a proof-of-concept studies of investigational antiretroviral therapies, VH4524184 <a href="https://www.benzinga.com/pressreleases/25/03/b44261960/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025-with-data-" target="_blank" rel="noreferrer noopener">(VH184) and VH4011499 (VH499)</a>.
Also Read: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39915897/pfizer-and-gsks-viiv-healthcares-two-drug-hiv-treatment-matches-gileads-three-drug-combo-in-major" target="_blank" rel="noreferrer noopener">Pfizer And GSK&#8217;s ViiV Healthcare&#8217;s Two-Drug HIV Treatment Matches Gilead&#8217;s Three-Drug Combo In Major Trial</a></li>
</ul>
VH184 demonstrated potency at all doses. After 10 days of monotherapy, the average decreases were -1.17, -2.15, and -2.31 log10 copies/mL for the 10mg, 50mg, and 300mg doses, respectively.
<ul>
<li>The maximum viral load decline (-2.69 log10) was observed in the 300mg dose. Additionally, no drug-resistance mutations were observed at the end of the study.</li>
<li>Long-acting formulations of VH184 in adults without HIV are being evaluated in an ongoing phase 1 study.</li>
</ul>
<ul>
<li>The trial of VH499 showed that all oral doses (25mg, 100mg, and 250mg) led to a decrease in HIV-1 viral load ranging from -2.2 log10 copies/mL in the 250mg arm to -1.8 log10 copies/mL in the 25mg and 100mg arms. VH499 was well tolerated, with all adverse events being mild to moderate in severity.</li>
<li>There were no adverse events leading to withdrawal, and no serious adverse events were reported</li>
<li>On day 11, one individual on the 25mg dose developed a single mutation associated with reduced susceptibility to capsid inhibitors.</li>
</ul>
ViiV Healthcare is majority owned by GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), with Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Shionogi as shareholders.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/management/25/03/44282015/cannabis-firm-cresco-labs-reports-mixed-q4-ceo-says-company-will-strategically-deploy-capital-to-create-growth-in-2025" target="_blank" rel="noreferrer noopener">Cannabis Firm Cresco Labs Reports Mixed Q4, CEO Says Company Will &#8216;Strategically Deploy Capital To Create Growth&#8217; In 2025</a></li>
</ul>

Biotech

Large Cap

Health Care

General

GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study

NDAQ

Nasdaq And Adena T. Friedman Enter Employment Agreement Relating To  Continuation Of Her Role As Chair And CEO Through January 1, 2030 - Filing

SCYX

SCYNEXIS 2024 GAAP EPS $(0.44) Down From $1.39 YoY, Sales $3.75M Down From $140.14M YoY

Graphic Packaging Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) has outperformed the market over the past 20 years by 1.24% on an annualized basis producing an average annual return of 9.33%. Currently, Graphic Packaging Holding has a market capitalization of $7.88 billion. 
Buying $1000 In GPK: If an investor had bought $1000 of GPK stock 20 years ago, it would be worth $5,618.84 today based on a price of $26.24 for GPK at the time of writing.
<h3>Graphic Packaging Holding's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741814238_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Graphic Packaging Holding Stock In The Last 20 Years

LEGH

Legacy Housing FY24 Revenue $184.2M, Down 2.6% YoY

On March 12, 2025, the Board of Directors of Kewaunee Scientific amended its existing share repurchase program initially approved on August 31, 2023, and in effect September 1, 2023.&nbsp;
The Board of Directors authorized the repurchase of up to an additional 100,000 shares of the Company's common stock under the existing share repurchase program, as amended, which does not have a specified expiration date.&nbsp;
The Program, as of the end of day March 12, 2025 and prior to this amendment, still had 11,176 shares authorized for repurchase which remain authorized for repurchase and are unaffected by this amendment.

Buybacks

KEQU

Kewaunee Scientific Amends Share Repurchase Program, Authorizing Up To An Additional 100,000 Shares

The gross proceeds to be received by the Company at closing are $10 million before deducting transaction-related expenses.

ARMP

Armata Enters $10M Secured Credit Agreement With Innoviva Strategic Opportunities LLC

Piper Sandler has upgraded Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>), a molecular diagnostic testing and precision medicine company.
Analyst David Westenberg says Myriad Genetics&#8217; management team set an overly aggressive LRP. Since then, two events—the loss of a private payer&#8217;s reimbursement on Genesight and an NCCN guideline language change—have led to an over 50% decline in the stock in the last six months.
Westenberg writes that Myriad Genetics risks missing this year&#8217;s guidance and might need to set 2026 expectations below the LRP.
&#8220;We think Myriad&#8217;s biggest remaining potential downside is expectations set by a previous CEO, and we believe the stock will find a bottom around this ~1x revenue range,&#8221; Piper Sandler writes.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43953008/myriad-genetics-faces-cost-restructuring-as-unitedhealthcare-ends-genesight-coverage-appoints-new-ceo" rel="noreferrer noopener">Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO</a>
BMO Capital writes Myriad Genetics has faced challenges in the urology and prostate testing market, losing some ground to Deciphera Pharmaceuticals and Veracyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>) in recent years.
However, the company has taken steps to stand out, including a new partnership with PATHOMIQ to integrate AI with molecular testing. Myriad Genetics plans to launch a test for patients after radical prostatectomy and radiation treatment later this year or early next year. This test will be offered alongside Prolaris as a combined option.
Piper Sandler writes that the stock has stabilized, allowing new CEO Sam Raha to reshape the business, set clear strategies and align expectations. The analyst has upgraded the stock from Neutral to Overweight, with a price target of $12.50, <a href="https://www.benzinga.com/quote/MYGN/analyst-ratings" target="_blank" rel="noreferrer noopener">up from $11.50</a>.
Price Action: MYGN stock is up 2.44% at $10.50 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44283318/gilead-presents-new-hiv-treatment-and-cure-research-data" target="_blank" rel="noreferrer noopener">Gilead Presents New HIV Treatment And Cure Research Data</a></li>
</ul>

Analyst Color

Upgrades

Analyst Ratings

MYGN

VCYT

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade

JPMorgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon is no stranger to making bold predictions about the economy. His latest comments suggest storm clouds <a href="https://www.benzinga.com/25/03/44270128/us-recession-probability-escalates-to-35-amid-tariffs-pimco-sounds-alarm">could be forming once again</a>.
What To Know: At the 2025 National Retirement Summit hosted by BlackRock and Semafor on Wednesday, Dimon warned that he sees a weakening of the economy and negative sentiment, according to an X <a href="https://x.com/SpencerHakimian/status/1899879996304273725">post</a> from Tolou Capital Management founder Spencer Hakimian. The post also indicates that Dimon believes tariffs are causing uncertainty.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x2A;JP MORGAN&#39;S CEO DIMON: SEEING WEAKENING IN ECONOMY, NEGATIVE SENTIMENT &#x2A;DIMON SAYS TARIFFS ARE CAUSING UNCERTAINTY Most important private sector human on earth telling it to you straight up.
&mdash; Spencer Hakimian (@SpencerHakimian) <a href="https://twitter.com/SpencerHakimian/status/1899879996304273725?ref_src=twsrc%5Etfw">March 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Semafor Principals editor Morgan Chalfant also reported similar details from the event in a separate X <a href="https://x.com/mchalfant16/status/1899878158389719290">post</a>. Chalfant noted that although Dimon said <a href="https://www.benzinga.com/25/02/43564020/consumer-sentiment-sinks-economist-flags-unusually-large-rise-in-inflation-perception">consumer sentiment is weakening</a>, the JPMorgan chief indicated that he doesn&#8217;t believe the average American &#8220;changes what they&#8217;re going to do&#8221; because of tariffs.
Dimon isn&#8217;t always spot-on with his predictions. In late 2022, he warned that an <a href="http://www.benzinga.com/news/22/10/29208975/jamie-dimon-warns-of-u-s-recession-in-6-9-months-says-jp-morgan-preparing-for-economic-hurricane" target="_blank" rel="noreferrer noopener">economic &#8220;hurricane&#8221;</a> was coming in mid-2023.
Dimon later walked back those comments after data showed otherwise.
&#8220;I shouldn't ever use the word hurricane, but &#8230; there were storm clouds,&#8221; Dimon <a href="https://www.benzinga.com/news/23/01/30358567/i-shouldnt-ever-use-the-word-hurricane-jamie-dimon-says-storm-clouds-remain-but-the-consumer-is-roll">said</a> in a 2023 interview.
It&#8217;s not clear if Dimon sees &#8220;storm clouds&#8221; over the economy this time around, but he at least appears to be taking a cautious stance. 
Price Action: <a href="http://benzinga.com/quote/jpm">JPMorgan shares</a> were up 0.61% at $230.50 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44280431/cpi-reactions">Inflation Moves In The &#8216;Right Direction&#8217; But Forecast Is Hazy, Economist Says</a></li>
</ul>
Photo: Shutterstock.

Events

Jamie Dimon Warns Of Economic Weakening, Negative Consumer Sentiment

<h3>Gainers</h3>
<ul>
<li>Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) stock moved upwards by 9.1% to $2.15 during Wednesday's after-market session. The market value of their outstanding shares is at $109.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Advantage Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADV#NASDAQ">ADV</a>) shares increased by 6.47% to $1.81. The market value of their outstanding shares is at $581.7 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) stock increased by 5.51% to $3.06. The company's market cap stands at $402.4 million. As per the news, the Q4 earnings report came out today. </li>
<li>Cumulus Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMLS#NASDAQ">CMLS</a>) shares rose 5.0% to $0.43. The company's market cap stands at $7.3 million. </li>
<li>Moving iMage Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#AMEX">MITQ</a>) shares increased by 4.99% to $0.58. The company's market cap stands at $5.7 million. </li>
<li>System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) stock increased by 4.82% to $0.5. The company's market cap stands at $35.3 million. The company's, Q4 earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Blue Hat Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHAT#NASDAQ">BHAT</a>) stock declined by 14.0% to $0.03 during Wednesday's after-market session. The company's market cap stands at $16.5 million. </li>
<li>Starbox Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STBX#NASDAQ">STBX</a>) stock decreased by 5.9% to $0.27. The market value of their outstanding shares is at $2.0 million. </li>
<li>Asset Entities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASST#NASDAQ">ASST</a>) stock fell 5.34% to $0.53. The company's market cap stands at $7.2 million. </li>
<li>Haoxi Health Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) stock declined by 5.2% to $1.46. The market value of their outstanding shares is at $4.1 million. </li>
<li>LQR House (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YHC#NASDAQ">YHC</a>) shares fell 4.47% to $1.93. The company's market cap stands at $43.7 million. </li>
<li>Able View Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABLV#NASDAQ">ABLV</a>) stock declined by 4.35% to $1.1. The market value of their outstanding shares is at $54.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-communication-services-stocks/" title="www.benzinga.com/money/best-communication-services-stocks/">www.benzinga.com/money/best-communication-services-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABLV

ASST

BHAT

CDLX

CMLS

MITQ

SEAT

STBX

12 Communication Services Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>TuHURA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HURA#NASDAQ">HURA</a>) stock increased by 17.4% to $2.46 during Wednesday's after-market session. The market value of their outstanding shares is at $104.0 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) stock moved upwards by 16.23% to $2.65. The market value of their outstanding shares is at $2.7 million. As per the press release, Q4 earnings came out today. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock increased by 12.64% to $0.8. The market value of their outstanding shares is at $18.4 million. </li>
<li>Scienture Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNX#NASDAQ">SCNX</a>) shares moved upwards by 12.41% to $1.46. The company's market cap stands at $12.5 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares rose 8.99% to $0.29. The company's market cap stands at $1.8 million. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock rose 8.19% to $0.75. The company's market cap stands at $128.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock decreased by 52.5% to $0.05 during Wednesday's after-market session. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares declined by 39.27% to $0.03. The company's market cap stands at $2.7 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 18.86% to $0.04. </li>
<li>Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) shares fell 9.98% to $0.08. The company's market cap stands at $2.0 million. </li>
<li>Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) stock declined by 9.76% to $3.7. The company's market cap stands at $115.1 million. As per the press release, Q4 earnings came out today. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock decreased by 7.03% to $0.25. The company's market cap stands at $4.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADTX

BSGM

BTMD

CPHI

CUTR

HEPA

HURA

MCRB

SCNX

SNES

SYRS

YCBD

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) stock moved upwards by 30.4% to $0.71 during Wednesday's after-market session. The market value of their outstanding shares is at $3.1 million. </li>
<li>FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) stock moved upwards by 13.8% to $7.09. The company's market cap stands at $133.9 million. The company's, Q4 earnings came out today. </li>
<li>Captivision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPT#NASDAQ">CAPT</a>) shares moved upwards by 6.22% to $0.51. The market value of their outstanding shares is at $16.6 million. </li>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) shares increased by 5.92% to $0.18. The market value of their outstanding shares is at $23.9 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares increased by 5.45% to $2.9. The company's market cap stands at $7.2 million. </li>
<li>T1 Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TE#NYSE">TE</a>) shares moved upwards by 5.28% to $1.59. The market value of their outstanding shares is at $223.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) stock fell 11.3% to $15.83 during Wednesday's after-market session. The market value of their outstanding shares is at $120.2 million. The company's, Q4 earnings came out today. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares decreased by 9.93% to $0.29. </li>
<li>CDT Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTG#NASDAQ">CDTG</a>) stock declined by 9.1% to $1.3. The company's market cap stands at $13.9 million. </li>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) stock fell 7.77% to $0.57. The market value of their outstanding shares is at $17.0 million. </li>
<li>High-Trend International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCO#NASDAQ">HTCO</a>) stock fell 6.98% to $1.6. The company's market cap stands at $89.2 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares fell 4.78% to $0.47. The company's market cap stands at $11.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

CAPT

CDTG

HTCO

POLA

PSIG

RAIL

RCMT

SGBX

VSTE

12 Industrials Stocks Moving In Wednesday's After-Market Session

Press Releases

BrightSpring Health Services, Inc. to Announce Third Quarter 2024 Financial Results on November 1, 2024

BrightSpring Health Services, Inc. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Guidance

BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®

BrightSpring Health Services, Inc. to Participate in Two Upcoming Investor Conferences

BrightSpring Health Services Announces Onco360® Has Been Selected as a Partner for Several New Drugs

BrightSpring Health Services, Inc. Announced Refinancing of Term Loan B

BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living

BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

BrightSpring Health Services, Inc. Announces Promotion of Jennifer Phipps to Chief Financial Officer

BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Increases Full Year 2025 Guidance

BTSG

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

BrightSpring Health

ニュース

最新ニュース BrightSpring Health (NASDAQ:BTSG) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル